Ticker

Shares of Siemens Healthineers AG (OTCMKTS:SMMNY - Get Free Report) have been assigned an average recommendation of "Buy" from the seven ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating, two have given a buy rating and three have issued a strong buy rating on

Siemens Healthineers AG (SMMNY) Q1 2026 Earnings Call Transcript

Revenue grew on a comparable basis as results in its imaging and precision therapy business units offset currency and tariff headwinds.

Siemens Healthineers reported first-quarter operating profit above market expectations on Thursday, as strong margin performance in its core imaging and cancer-care units helped cushion a slump in its diagnostics business and adverse currency exchange rates.

Siemens Healthineers (SEMHF) is undervalued, offering strong safety and upside, and remains a top 'BUY' pick for 2026. Key risks center on muted China growth, but ex-China performance is robust, with Imaging and Varian segments driving future gains. I maintain my share price target, with fair value estimates, implying 15%+ annualized upside even with conservative assumptions.